Lords Mark Industries sets ₹1,550 crore FY27 revenue guidance

scanx
Reviewed by
Anirudha BScanX News Team
Key Highlights
  • Revenue guidance for FY27 set at ₹1,550 crore with EBITDA margin of 20.8%
  • MedTech segment expected to contribute ₹825 crore, surpassing renewable energy
  • Confirmed order book for dialysis machines exceeds 500 units
  • Renewable energy division holds ₹2,000 crore order book through 2030
  • Operating cash flow expected to turn positive in FY27 or early FY28
powered bylight_fuzz_icon
50742525

*this image is generated using AI for illustrative purposes only.

Lords Mark Industries Limited provided financial guidance for FY27 during an investor summit on September 10, 2026, projecting consolidated revenue of ₹1,550 crore. The management expects EBITDA margins to reach 20.8% and PAT margins of 12.8% for the fiscal year. This outlook reflects a strategic shift toward higher-margin medical technology products alongside its established renewable energy business.

Financial Outlook and Segment Mix

The company anticipates that the MedTech and IVD segments will contribute approximately ₹825 crore to the total revenue, representing more than half of the top line. Management indicated that MedTech is expected to take the lead over the renewable energy business in terms of revenue contribution in the coming years.

The margin profile varies significantly across business verticals. The IVD and MedTech segment is projected to deliver an EBITDA margin of 23.65% and a PAT margin of 15.46%. In contrast, the renewable energy division is expected to report lower margins, with EBITDA at 17.41% and PAT at 11.8%.

Segment Projected Revenue (₹ crore) EBITDA Margin PAT Margin
IVD & MedTech 825 23.65% 15.46%
Renewable Energy ~725 17.41% 11.80%
Consolidated 1,550 20.80% 12.80%

MedTech Growth Drivers

Lords Mark highlighted several new product launches and partnerships driving the MedTech vertical. The company acquired Renalytics in 2025, which manufactures India's first AI-powered dialysis machine. Management confirmed a confirmed order book of over 500 dialysis machines and plans to operate 50 dialysis centers by March 2027, up from 15 currently operational centers.

Other key developments include:

  • Launch of the proprietary sickle cell screening device, aligned with the National Sickle Cell Elimination Mission.
  • Exclusive distribution rights for Dozee, a contactless remote patient monitoring system.
  • Recent US export orders worth close to $1 million for surgical products.
  • Plans to launch two oncology cancer care centers in Vapi and Solapur by June 2027.

Renewable Energy and Order Book

The renewable energy division continues to rely on long-term government contracts. Management disclosed a confirmed order book worth ₹2,000 crore extending through 2030, with expectations of an additional ₹1,000 crore from new contracts. The company remains a key partner for Philips in lighting design, contributing to 26% of Indian railway lighting projects.

What the Numbers Show

The projected revenue mix indicates a significant structural shift in the company's earnings quality. With MedTech contributing roughly 53% of the guided revenue but commanding nearly 6 percentage points higher EBITDA margins than the renewable energy segment, the weighted average profitability is set to expand. This divergence suggests that the growth trajectory in FY27 will be driven less by volume in low-margin infrastructure projects and more by high-margin consumable sales in diagnostics and devices.

Balance Sheet and Liquidity

Addressing investor concerns regarding working capital, management clarified that consolidated receivables stood at ₹450 crore against a full-year revenue of ₹1,290 crore. The company stated these levels are within historical controls. Regarding cash flows, management noted that while FY26 cash flow was negative due to capex on new product streams, operating cash flow is expected to turn positive in FY27 or by Q2FY28 at the latest.

The company also outlined plans to meet the Minimum Public Shareholding (MPS) requirement through a dilution of 4-5%, comprising a 3% Offer for Sale (OFS) where promoters infuse funds back into the company, and a 2% issuance of preference or equity shares.

How might the planned 4-5% equity dilution to meet Minimum Public Shareholding requirements impact existing shareholder value and promoter control in the near term?

What are the specific regulatory or reimbursement hurdles Lords Mark faces in scaling its 50 dialysis centers and integrating AI-powered Renalytics technology into public healthcare systems?

Given the significant margin disparity between MedTech and Renewable Energy, how vulnerable is the consolidated EBITDA target to potential delays in the execution of high-margin MedTech product launches?

like17
dislike

Lords Mark Industries approves 3% promoter OFS for MPS compliance

scanx
Reviewed by
Anirudha BScanX News Team
Key Highlights
  • Lords Mark Industries approved a promoter Offer for Sale of up to 3% of equity shares
  • The move aims to achieve Minimum Public Shareholding compliance norms
  • The proposal was recommended by the MPS Committee at the September 5, 2026 board meeting
  • Directors are authorized to file necessary disclosures with stock exchanges and regulators
powered bylight_fuzz_icon
50156637

*this image is generated using AI for illustrative purposes only.

Lords Mark Industries Limited approved an Offer for Sale by its promoters to address Minimum Public Shareholding requirements. The board authorized the sale of up to 3% of the paid-up equity share capital during its meeting on September 5, 2026.

The decision follows a recommendation from the Minimum Public Shareholding Committee. The proposed transaction is subject to applicable laws, regulations, and necessary approvals from the respective promoters. The company aims to achieve the statutory MPS requirement through this corporate action.

Board Authorization

The Board of Directors authorized appropriate officers to execute all necessary steps for the Offer for Sale. This includes making requisite disclosures, filings, and applications with stock exchanges and regulatory authorities. The meeting commenced at 3:00 pm and concluded at 3:30 pm.

Mr. Sachidanand Hariram Upadhyay, Managing Director, signed the intimation letter addressed to the BSE Limited. The company, formerly known as Lords Mark India Limited and Kratos Energy & Infrastructure Limited, operates under CIN L35103MH1979PLC021614.

How might the 3% promoter stake sale impact the stock's liquidity and trading volume in the near term?

What are the potential implications for minority shareholders regarding potential dilution or price volatility during the Offer for Sale period?

Could this move signal broader corporate restructuring or promoter exit strategies beyond just meeting the Minimum Public Shareholding requirement?

like17
dislike

More News on lord's mark industries